Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum ...
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...
A senior executive at BeiGene is under investigation by Chinese authorities, multiple local media outlets report. | A senior ...
Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an ...
EY recently published their 18th annual Pulse of the MedTech Industry report, highlighting | This week on "The Top Line," ...
UK health secretary warns GLP-1s not for 'body beautiful picture for Instagram' amid misuse concerns
The U.K. government issued a new warning aimed at the misuse of GLP-1 therapies by those who don’t qualify for the meds but are instead using them for quick-fix weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback